Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 195-214 , August 2002

The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures

  • Janine Nuver

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • Andries J Smit

      Affiliations

    • Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • Aleida Postma

      Affiliations

    • Department of Pediatric Oncology, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • Dirk Th Sleijfer

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • Jourik A Gietema

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorrespondence to: Jourik A. Gietema, Department of Medical Oncology, University Hospital Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands, Tel.: +31-50-3611334; Fax: +31-50-3614862

References 

  1. Sheldon T. Cancer survival rates continue to rise in the Netherlands. BMJ. 2001;322:1509
  2. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 2000;18:1725–1732
  3. Strumberg D, Brugge S, Korn M, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol. 2002;13:229–236
  4. Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J. Clin. Endocrinol. Metab. 1996;81:3051–3055
  5. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone marrow transplantation in childhood. Lancet. 2000;356:993–997
  6. Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J. Pediatr. 1995;127:63–67
  7. Heikens J, Ubbink MC, van der Pal HP, Bakker PJ, Fliers E, Smilde TJ, et al. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer. 2000;88:2116–2121
  8. Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 2001;23:424–430
  9. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333–1445
  10. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ. 1994;309:162–166
  11. Hudson MM, Jones D, Boyett J, Sharp GB, Pui CH. Late mortality of long-term survivors of childhood cancer. J. Clin. Oncol. 1997;15:2205–2213
  12. Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J. Clin. Oncol. 1999;17:3207–3215
  13. Nicholson HS, Fears TR, Byrne J. Death during adulthood in survivors of childhood and adolescent cancer. Cancer. 1994;73:3094–3102
  14. Hawkins MM, Kingston JE, Kinnier Wilson LM. Late deaths after treatment for childhood cancer. Arch. Dis. Child. 1990;65:1356–1363
  15. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit M-EJ, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the childhood cancer survivor study. J. Clin. Oncol. 2001;19:3163–3172
  16. Moller TR, Garwicz S, Barlow L, Falck-Winther J, Glattre E, Olafsdottir G, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J. Clin. Oncol. 2001;19:3173–3181
  17. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  18. Scheen AJ. Insulin resistance syndrome and atherosclerotic cardiovascular disease. Acta. Clin. Belg. 1996;51:65–69
  19. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  20. Reaven G. Syndrome X: 10 years after. Drugs. 1999;58(Suppl. 1):19–20
  21. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am. J. Epidemiol. 1998;148:958–966
  22. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715–722
  23. Meigs JB, D’Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997;46:1594–1600
  24. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs. 1999;58(Suppl. 1):7–10
  25. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(Suppl. 2):S9–S13
  26. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet. 2001;358:1400–1404
  27. Bjorntorp P, Rosmond R. The metabolic syndrome—a neuroendocrine disorder. Br. J. Nutr. 2000;83(1):S49–S57
  28. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J. Endocrinol. Invest. 1999;22:41–46
  29. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int. J. Obes. Relat. Metab. Disord. 2000;24(Suppl. 2):S50–S55
  30. Golub MS. The adrenal and the metabolic syndrome. Curr. Hypertens. Rep. 2001;3:117–120
  31. Talvensaari K, Knip M. Childhood cancer and later development of the metabolic syndrome. Ann. Med. 1997;29:353–355
  32. Kauppila M, Koskinen P, Irjala K, Remes K, Viikari J. Long-term effects of allogeneic bone marrow transplantation BMT on pituitary, gonad, thyroid and adrenal function in adults. Bone Marrow Transplant. 1998;22:331–337
  33. Oberfield SE, Chin D, Uli N, David R, Sklar C. Endocrine late effects of childhood cancers. J. Pediatr. 1997;131:S37–S41
  34. Duffner PK, Cohen ME, Voorhess ML, MacGillivray MH, Brecher ML, Panahon A, et al. Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer. 1985;56:2189–2193
  35. Shalet SM. Endocrine consequences of treatment of malignant disease. Arch. Dis. Child. 1989;64:1635–1641
  36. Shalet SM, Brennan BM. Growth and growth hormone status following treatment for childhood leukaemia. Horm. Res. 1998;50:1–10
  37. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, et al. Growth hormone response to a growth hormone-releasing hormone stimulation test in a population-based study following cranial irradiation of childhood brain tumors. Horm. Res. 2000;54:53–59
  38. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78:539–545
  39. Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am. J. Cardiol. 1987;60:771–777
  40. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897–901
  41. Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43:599–603
  42. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli LA, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40:101–104
  43. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the telecom study. Diabetologia. 1992;35:173–177
  44. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta. Physiol. Scand. 1992;146:505–510
  45. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J. Clin. Endocrinol. Metab. 1987;64:960–963
  46. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care. 1994;17:405–411
  47. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 1990;132:895–901
  48. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 1992;117:807–811
  49. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am. J. Med. 2001;110:563–572
  50. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 2000;85:2670–2677
  51. Bigras JL, Fournier A, McCrindle BW, Cartwright D, Davignon A, Leclerc JM. Functional cardiac disturbances related to chemotherapy independent of anthracycline use in children with neoplastic disease. Am. J. Cardiol. 1995;75:101–103
  52. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J. Clin. Endocrinol. Metab. 1996;81:3469–3475
  53. Munzer T, Harman SM, Hees P, Shapiro E, Christmas C, Bellantoni MF, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J. Clin. Endocrinol. Metab. 2001;86:3604–3610
  54. Friedl KE, Jones RE, Hannan CJ, Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J. Clin. Endocrinol. Metab. 1989;68:971–975
  55. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 1996;81:4358–4365
  56. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994;79:561–567
  57. Gutai J, LaPorte R, Kuller L, Dai W, Falvo-Gerard L, Caggiula A. Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions. Am. J. Cardiol. 1981;48:897–902
  58. von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J. Clin. Endocrinol. Metab. 1997;82:3367–3372
  59. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann. Int. Med. 1992;116:967–973
  60. Kouri EM, Pope HG, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin. J. Sport Med. 1996;6:152–157
  61. Meriggiola MC, Marcovina S, Paulsen CA, Bremner WJ. Testosterone enanthate at a dose of 200mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl. 1995;18:237–242
  62. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J. Clin. Endocrinol. Metab. 2001;86:1026–1033
  63. Tyagi A, Rajalakshmi M, Jeyaraj DA, Sharma RS, Bajaj JS. Effects of long-term use of testosterone enanthate. II. Effects on lipids, high and low density lipoprotein cholesterol and liver function parameters. Int. J. Androl. 1999;22:347–355
  64. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996;121:35–43
  65. Berglund L, Carlstrom K, Stege R, Gottlieb C, Eriksson M, Angelin B, et al. Hormonal regulation of serum lipoprotein a levels: effects of parenteral administration of oestrogen or testosterone in males. J. Clin. Endocrinol. Metab. 1996;81:2633–2637
  66. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation. 1996;94:2614–2619
  67. Levine S, Likoff W. The therapeutic value of testosterone propionate in angina pectoris. N. Engl. J. Med. 1943;229:770–772
  68. Lesser M. Testosterone propionate therapy in one hundred cases of angina pectoris. J. Clin. Endocrinol. 1946;6:549–557
  69. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischaemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–1670
  70. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br. J. Cancer. 1996;73:1108–1114
  71. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer. 2001;91:1297–1303
  72. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613–621
  73. Fukui M, Koyama M, Nakagawa Y, Itoh Y, Nakamura N, Kondo M. Castration and diabetes. Diabetes Care. 2000;23:1032–1033
  74. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 2001;86:4261–4267
  75. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin. Endocrinol. (Oxf). 2001;55:315–324
  76. Mendelsohn ME, Karas RH. The protective effects of oestrogen on the cardiovascular system. N. Engl. J. Med. 1999;340:1801–1811
  77. Effects of Oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Oestrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273: 199–208
  78. Herrington DM, Espeland MA, Crouse III JR, Robertson J, Riley WA, McBurnie MA, et al. Oestrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler. Thromb. Vasc. Biol. 2001;21:1955–1961
  79. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, et al. Abnormal vascular function and hypertension in mice deficient in oestrogen receptor β. Science. 2002;295:505–508
  80. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of oestrogen receptor beta (ESR2) gene polymorphism with blood pressure. J. Hum. Genet. 2000;45:327–330
  81. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public. Health. 1998;19:55–72
  82. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Oestrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  83. Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D, Furberg CD, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch. Int. Med. 2001;161:1709–1713
  84. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Int. Med. 2000;133:933–941
  85. Ariyo AA, Villablanca AC. Oestrogens and lipids. Can HRT designer oestrogens, and phytoestrogens reduce cardiovascular risk markers after menopause?. Postgrad. Med. 2002;111:23–30
  86. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33:65–76
  87. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 2001;19:3306–3311
  88. Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant. 1998;21:287–290
  89. Bath LE, Critchley HO, Chambers SE, Anderson RA, Kelnar CJ, Wallace WH. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br. J. Obstet. Gynaecol. 1999;106:1265–1272
  90. Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28:67–75
  91. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J. Clin. Endocrinol. Metab. 1996;81:4453–4457
  92. Johansson BW, Kaij L, Kullander S, Lenner HC, Svanberg L, Astedt B. On some late effects of bilateral oophorectomy in the age range 15–30 years. Acta Obstet. Gynecol. Scand. 1975;54:449–461
  93. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann. Med. 1992;24:465–468
  94. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285–288
  95. Bates AS, Van’t Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 1996;81:1169–1172
  96. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. (Oxf). 1997;46:75–81
  97. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431
  98. Alford FP, Hew FL, Christopher MC, Rantzau C. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy. J. Endocrinol. Invest. 1999;22:28–32
  99. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 1998;83:382–395
  100. Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 1994;14:434–437
  101. Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin. Endocrinol. (Oxf). 1999;50:457–464
  102. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin. Endocrinol. (Oxf). 2002;56:493–501
  103. Napoli R, Guardasole V, Matarazzo M, Palmieri EA, Oliviero U, Fazio S, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002;39:90–95
  104. Capaldo B, Guardasole V, Pardo F, Matarazzo M, Di Rella F, Numis F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation. 2001;103:520–524
  105. Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 1997;82:1378–1381
  106. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 1993;77:1671–1676
  107. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J. Clin. Endocrinol. Metab. 1999;84:2373–2380
  108. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 2000;85:3762–3769
  109. Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J. Pediatr. Hematol. Oncol. 1995;17:167–171
  110. Lannering B, Rosberg S, Marky I, Moell C, Albertsson-Wikland K. Reduced growth hormone secretion with maintained periodicity following cranial irradiation in children with acute lymphoblastic leukaemia. Clin. Endocrinol. (Oxf). 1995;42:153–159
  111. Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Int. J. Radiat. Oncol. Biol. Phys. 1996;34:843–851
  112. Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J. Clin. Oncol. 1994;12:916–924
  113. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh.). 1993;129:195–200
  114. Osman F, Gammage MD, Franklyn JA. Thyroid disease and its treatment: short-term and long-term cardiovascular consequences. Curr. Opin. Pharmacol. 2001;1:626–631
  115. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid. 2000;10:665–679
  116. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J. Clin. Endocrinol. Metab. 2001;86:4591–4599
  117. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf). 1995;43:55–68
  118. Ladenson PW, Wilson MC, Gardin J, Krommal R, Kuller L, Tracy R, et al. Relationship of subclinical hypothyroidism to cardiovascular risk factors and disease in an elderly population. Thyroid. 1994;4(Suppl. 1):S18
  119. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann. Int. Med. 2000;132:270–278
  120. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid. 1997;7:411–414
  121. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann. Int. Med. 1984;101:18–24
  122. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin. Endocrinol. (Oxf). 1988;29:63–75
  123. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 2000;85:3227–3232
  124. Turner SL, Tiver KW, Boyages SC. Thyroid dysfunction following radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:279–283
  125. Mercado G, Adelstein DJ, Saxton JP, Secic M, Larto MA, Lavertu P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer. 2001;92:2892–2897
  126. Ricardi U, Corrias A, Einaudi S, Genitori L, Sandri A, di Montezemolo LC, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:1287–1294
  127. Thomas O, Mahe M, Campion L, Bourdin S, Milpied N, Brunet G, et al. Long-term complications of total body irradiation in adults. Int. J. Radiat. Oncol. Biol. Phys. 2001;49:125–131
  128. Keilholz U, Max R, Scheibenbogen C, Wuster C, Korbling M, Haas R. Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. Cancer. 1997;79:1617–1622
  129. Thomas BC, Stanhope R, Plowman PN, Leiper AD. Endocrine function following single fraction and fractionated total body irradiation for bone marrow transplantation in childhood. Acta Endocrinol. (Copenh.). 1993;128:508–512
  130. Ogilvy-Stuart AL, Clark DJ, Wallace WH, Gibson BE, Stevens RF, Shalet SM, et al. Endocrine deficit after fractionated total body irradiation. Arch. Dis. Child. 1992;67:1107–1110
  131. Sklar CA, Kim TH, Ramsay NK. Thyroid dysfunction among long-term survivors of bone marrow transplantation. Am. J. Med. 1982;73:688–694
  132. Cutuli B, Quentin P, Rodier JF, Barakat P, Grob JC. Severe hypothyroidism after chemotherapy and locoregional irradiation for breast cancer. Radiother. Oncol. 2000;57:103–105
  133. Bruning PF, Bonfrer JM, Hart AA, Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer. 1988;58:497–499
  134. Joensuu H, Viikari J. Thyroid function after postoperative radiation therapy in patients with breast cancer. Acta Radiol. Oncol. 1986;25:167–170
  135. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet. 1998;352:391–396
  136. de Valk HW. Magnesium in diabetes mellitus. Neth. J. Med. 1999;54:139–146
  137. Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, Szklo M. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann. Epidemiol. 1999;9:159–165
  138. Shivakumar K. Model of cardiovascular injury in magnesium deficiency. Med. Hypotheses. 2001;56:110–113
  139. van de Loosdrecht AA, Gietema JA, van der Graaf WT. Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia. Acta Oncol. 2000;39:239–240
  140. Gietema JA, Meinardi MT, van der Graaf WT, Uges DR, Sleijfer DT. Magnesium and phosphorus. Lancet. 1998;352:1476
  141. Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch. Int. Med. 1988;148:2415–2420
  142. Rosolova H, Mayer O, Reaven G. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects. J. Clin. Endocrinol. Metab. 1997;82:3783–3785
  143. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993;21:1024–1029
  144. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J. Clin. Epidemiol. 1995;48:927–940
  145. Rosolova H, Mayer O, Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. Metabolism. 2000;49:418–420
  146. de Valk HW, Verkaaik R, van Rijn HJ, Geerdink RA, Struyvenberg A. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. Diabet. Med. 1998;15:503–507
  147. Gullestad L, Jacobsen T, Dolva LO. Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. Diabetes Care. 1994;17:460–461
  148. Eibl NL, Kopp HP, Nowak HR, Schnack CJ, Hopmeier PG, Schernthaner G. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. Diabetes Care. 1995;18:188–192
  149. Manthey J, Stoeppler M, Morgenstern W, Nussel E, Opherk D, Weintraut A, et al. Magnesium and trace metals: risk factors for coronary heart disease? Association between blood levels and angiographic findings. Circulation. 1981;64:722–729
  150. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am. J. Clin. Nutr. 1987;45:469–475
  151. Van Leer EM, Seidell JC, Kromhout D. Dietary calcium, potassium, magnesium and blood pressure in the Netherlands. Int. J. Epidemiol. 1995;24:1117–1123
  152. Kesteloot H, Joossens JV. The relationship between dietary intake and urinary excretion of sodium, potassium, calcium and magnesium: Belgian Interuniversity Research on Nutrition and Health. J. Hum. Hypertens. 1990;4:527–533
  153. He J, Tell GS, Tang YC, Mo PS, He GQ. Relation of electrolytes to blood pressure in men. The Yi people study. Hypertension. 1991;17:378–385
  154. Witteman JC, Willett WC, Stampfer MJ, Colditz GA, Sacks FM, Speizer FE, et al. A prospective study of nutritional factors and hypertension among US women. Circulation. 1989;80:1320–1327
  155. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, et al. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992;86:1475–1484
  156. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer. 1999;83:866–869
  157. Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. Arch. Int. Med. 1984;144:2347–2348
  158. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1205–1211
  159. Koch Nogueira PC, Hadj-Aissa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr. Nephrol. 1998;12:572–575
  160. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med. Pediatr. Oncol. 1997;28:35–40
  161. Brock PR, Koliouskas DE, Barratt TM, Yeomans E, Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. J. Pediatr. 1991;118:531–534
  162. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. Clin. Oncol. 1996;14:2923–2932
  163. Fossa SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology. 1995;52:300–305
  164. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann. Oncol. 2002;13:222–228
  165. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: A series of 15 patients. Med. Pediatr. Oncol. 1995;24:352–361
  166. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am. J. Med. 1978;65:823–832
  167. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischaemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann. Intern. Med. 1986;105:48–51
  168. Icli F, Karaoguz H, Dincol D, Demirkazik A, Gunel N, Karaoguz R, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–593
  169. Rodriguez J, Collazos J, Gallardo M, Hernando G. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann. Pharmacother. 1995;29:138–139
  170. Gerl A, Clemm C, Schleuning M, Wilmanns W. Fatal cerebrovascular accident associated with chemotherapy for testicular cancer. Eur. J. Cancer. 1993;29A:1220–1221
  171. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J. Clin. Oncol. 2000;18:2169–2178
  172. Gietema JA, Sleijfer DTh, Willemse PHB, Schraffordt Koops H, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Int. Med. 1992;116:709–715
  173. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother. Pharmacol. 1987;19:253–256
  174. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J. Clin. Oncol. 1988;6:1239–1247
  175. Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DTh, Williams B, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J. Clin. Oncol. 1989;7:1099–1104
  176. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J. Clin. Oncol. 1986;4:1405–1417
  177. Shi Y, Inoue S, Shinozaki R, Fukue K, Kougo T. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn. J. Cancer Res. 1998;89:757–767
  178. Kohn S, Fradis M, Podoshin L, Ben David J, Zidan J, Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct. Pathol. 1997;21:289–299
  179. Ito H, Okafuji T, Suzuki T. Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessels. 1995;10:178–184
  180. Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 1974;77:185–197
  181. Dirix LY, Libura M, Libura J, Vermeulen PB, De Bruijn EA, van Oosterom AT. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 1997;8:859–868
  182. Phan SH, Gharee-Kermani M, Wolber F, Ryan US. Bleomycin stimulates production of transforming growth factor-beta by rat pulmonary artery endothelial cells. Chest. 1991;99:66S
  183. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs. 2001;61:641–684
  184. Schuchter L, Hensley ML, Meropol NJ, Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2002;20:2895–2903
  185. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2001;37:1344–1350
  186. Dell’Omo G, Bandinelli S, Penno G, Pedrinelli R, Mariani M. Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men. Clin. Pharmacol. Ther. 2000;68:427–434
  187. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, et al. Vascular effects of oestrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99:354–360
  188. Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J. Am. Coll. Cardiol. 1998;32:711–716
  189. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350
  190. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544
  191. Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21:350–359
  192. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403
  193. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50:856–861
  194. Carlsen SM, Rossvoll O, Bjerve KS, Folling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J. Int. Med. 1996;239:227–233

☆ Supported by Grant RUG2000-2177 from the Dutch Cancer Society.

PII: S0305-7372(02)00038-5

Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 195-214 , August 2002

Article Tools